Treatment pattern and clinical outcomes in multiple myeloma patients in Japan using the Medical Data Vision claims database
Source : https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0283931
Multiple myeloma therapy has made remarkable progress with the advent of new drugs. We explored the treatment pattern and outcomes in Japanese patients with multiple myeloma using the Medical Data...
Conclusions/Relevance: Thus, this study revealed that recent diversification of treatment options is preferred and contributes to improved outcomes in the clinical practice of multiple myeloma in Japan.
RNA silencing of GM-CSF in CAR-T cells reduces the secretion of multiple inflammatory cytokines - Investigational New Drugs
Source : https://link.springer.com/article/10.1007/s10637-023-01344-9
Chimeric antigen receptor T (CAR-T) cell therapy has become a research hotspot in the field of hematological malignancies. However, CAR-T cell therapy can lead to immunotherapy-associated side effects including cytokine...
Conclusion: We introduced a new method to reduce GM-CSF secretion from CAR-T cells by inserting the GM-CSF shRNA-expression cassette in the CAR vector. This approach can be applied on any newly-developed CAR construct. The manufacture of GM-CSFKD CAR-T cells does not require repeated transfection, and the knockdown efficiency is more...
HBV reactivation in patients with chronic or resolved HBV infection following BCMA-targeted CAR-T cell therapy - Bone Marrow Transplantation
Source : https://www.nature.com/articles/s41409-023-01960-2
B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T cell (CAR-T) therapy is used for refractory or relapsed multiple myeloma (r/r MM). Concern of the safety and efficacy of CAR-T cell therapy...
Relevance: In this study, we retrospectively reviewed 99 patients with r/r MM treated with BCMA-targeted CAR-T cell therapy, of which 7 (7.1%) patients had chronic HBV infection, 43 (43.4%) with resolved HBV infection, and the remaining 49 (49.49%) HBV-uninfected.
All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma
Source : https://jitc.bmj.com/content/11/3/e006325
Background Immunotherapies targeting CD38 have demonstrated salient efficacy in relapsed/refractory multiple myeloma (MM). However, loss of CD38 antigen and outgrowth of CD38 negative plasma cells have emerged as a major...
Conclusion: This study elucidates a mechanism of ATRA in regulating CD38 expression and expands the clinical potential of ATRA in improving immunotherapies against CD38 in patients with MM.
Safety and efficacy of BCMA CAR-T cell therapy in older patients with multiple myeloma
Source : https://www.sciencedirect.com/science/article/abs/pii/S2666636723011715?via=ihub
Available online 17 March 2023 Author links open overlay panel, , , , , , , , , , Rahul Banerjee 4 5 Show more * BCMA CAR-T therapy is...
Conclusions: While limited by small sample size and unmeasured confounders, our retrospective analysis did not demonstrate significant increases in CAR-T toxicity among older patients. This included toxicities associated with geriatric populations such as falls and delirium. Our paradoxical finding of borderline better OS among patients aged...